Skip to main content

CAR T-Cell Translation: The State of the Art

Sponsored by

This event is over.

Event Details:

 CAR T-cell therapy has transcended the realm of promising research to become a game-changing FDA-approved treatment, offering newfound hope to hundreds of children and young adults facing once-incurable cancer.  Join us to discuss current advances in CAR T-cell therapy and the future of this treatment.

Topics include:

- Leveraging the translational CAR experience to enhance clinical outcomes
- Unraveling the mechanisms of antigen loss relapse after CD19 therapies in ALL
- GD2-CAR T-cell therapy for diffuse intrinsic pontine glioma and spinal cord diffuse midline glioma 
- Harnessing reverse translational research to optimize CAR T cells for children
- Tumor inflammation-associated neurotoxicity

Registration for all practitioners - free
To register for this activity, please click HERE

AMA PRA Category 1 Credits™ (1.00 hours), Non-Physician Participation Credit (1.00 hours)

Target Audience
Specialties - Oncology, Oncology, Pediatrics
Professions - Fellow/Resident, Non-Physician, Physician

At the conclusion of this activity, learners should be able to:

  • Describe how CAR T cell research is translated into the clinical environment
  • Determine whether CAR T-cell therapy might be a good fit for a patient
  • Review the current limitations of CAR T-cell therapy and what is being done to overcome them
  • Discuss new applications of CAR T-cell therapy in a growing group of cancers

In support of improving patient care, Stanford Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Credit Designation 
American Medical Association (AMA) 

Stanford Medicine designates this Live Activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

1 person is interested in this event